Schedule a Meeting
With sepsis, every hour counts
Target therapy sooner, with species identification before the second dose of empiric therapy
LEARN MORE

The first and only FDA-cleared diagnostic tests to provide species identification of sepsis-causing bacterial and fungal pathogens, directly from a whole blood sample and independent of a positive blood culture.

T2Candida Case Study
Secondary Candidemia in Critically Ill COVID-19 Patient
READ CASE STUDY

T2Candida enabled the detection of candidemia 29 hours before a positive blood culture was returned. Early detection allowed for the rapid initiation of antifungal therapy in a critically ill COVID-19 patient.

Enhancing the standard of care.

  • Reduce time to detection & species ID
  • Target therapy sooner
  • Reduce costs and length of stay
  • Enhance antimicrobial stewardship
  • Improve outcomes for patients
Learn More

With T2 Biosystems, hospitals can identify sepsis-causing pathogens faster and more accurately than the standard of blood culture alone

Hospitals trust in T2 technology

Gregorio Marañón Hospital in Madrid, Spain
Two 2018 studies from Gregorio Marañón Hospital in Madrid, Spain.
Learn More
Rigshospitalet, Denmark
"T2Candida was superior to blood culture and mannan antigen and may improve diagnosis."
Learn More
Gemelli Hospital, Italy
66.7% of the clinically infected patients missed by blood culture were correctly identified by T2Bacteria
Learn More
La Paz Hospital University, Spain
T2Candia Panel contributed to the healthy discharge of a 1-year-old transplant patient.
Learn More

Patient Case Studies

Real stories about the positive impact of T2 Biosystems on clinical decisions and outcomes

Targeted Antibiotic Therapy in Endocarditis Case with T2Bacteria

Numbers don't lie.

Sepsis is a burden on healthcare and patients, contributing to:

∼50 million
cases per year
11 million
deaths annually, worldwide.
1 in 5
deaths worldwide
Integrate T2 Biosystems Panels into your hospital today!
Learn More

T2 BIOSYSTEMS OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.

© 2022 T2 Biosystems, Inc.

JOIN IN ON TWITTER

SITEMAP

FOLLOW US ON SOCIAL

Linkedin-in Twitter

Please tell us where you are visiting from: United States | Outside the United States